IPM November 2025 Sales Data Analysis

December 12, 2025

IPM Momentum, Innovation Waves & the AQI-Driven Respiratory Surge — What Pharma Leaders Must Know Going Into 2026

By MedicinMan Editorial Team

The Indian Pharmaceutical Market (IPM) continues to demonstrate structural resilience and strong forward momentum. The latest PharmaTrac Acquaint – Nov’25 dataset provides rich insights into market drivers, therapy trends, competitive shifts and innovation flows that will define the industry’s direction in 2026.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Topics

Navigating India’s Diverging Health Landscape and Field Force Optimisation

Mounjaro to Orforglipro: Lilly’s $6 Billion Bet on the Next GLP‑1 Revolution

IPM November 2025 Sales Data Analysis

Free Membership Required

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

China’s Biopharma Strategy: A Warning and Opportunity for India

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

Who Is Accountable for the Medicine in Your Hand?

Topics

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

China’s Biopharma Strategy: A Warning and Opportunity for India

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

Who Is Accountable for the Medicine in Your Hand?

Who Profits From Trust?

The Great Healthcare Dilemma: Who Will Own the Next Indian Hospital?

Indian Pharma’s Three Deficits—and Three Potential Dividends

Related Articles

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

Will Mounjaro Disrupt Existing Therapy Areas Like Cardiology?

Company

Headlines

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

China’s Biopharma Strategy: A Warning and Opportunity for India

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

Newsletter